SPR 抗体 (AA 101-200) (AbBy Fluor® 350)
-
- 抗原 See all SPR 抗体
- SPR (Sepiapterin Reductase (SPR))
-
抗原表位
- AA 101-200
-
适用
- 人, 小鼠, 大鼠
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This SPR antibody is conjugated to AbBy Fluor® 350
-
应用范围
- Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- 交叉反应
- 人, 小鼠, 大鼠
- 预测反应
- Pig,Horse,Rabbit
- 纯化方法
- Purified by Protein A.
- 免疫原
- KLH conjugated synthetic peptide derived from human Sepiapterin reductase
- 亚型
- IgG
- Top Product
- Discover our top product SPR Primary Antibody
-
anti-Sepiapterin Reductase (SPR) antibody
SPR 适用: 人, 大鼠 WB, IHC, IF, FACS, IHC (p) 宿主: 小鼠 Monoclonal 4F5 unconjugated
anti-Sepiapterin Reductase (SPR) antibodySPR 适用: 人, 猴 WB, IHC, FACS, IHC (p) 宿主: 小鼠 Monoclonal 2C6 unconjugated
anti-Sepiapterin Reductase (SPR) antibodySPR 适用: 人, 猴 WB, IF, FACS 宿主: 小鼠 Monoclonal 3D6 unconjugated
anti-Sepiapterin Reductase (SPR) (AA 1-261) antibodySPR 适用: 小鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Sepiapterin Reductase (SPR) (AA 164-260) antibodySPR 适用: 人 WB, ELISA 宿主: 小鼠 Polyclonal unconjugated
anti-Sepiapterin Reductase (SPR) (AA 164-260) antibodySPR 适用: 人 WB, ELISA, IP 宿主: 小鼠 Monoclonal 4F2 unconjugated
anti-Sepiapterin Reductase (SPR) antibodySPR 适用: 人 WB, IF, IP, ICC, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Sepiapterin Reductase (SPR) (AA 1-261) antibodySPR 适用: 人 WB, IP 宿主: 兔 Polyclonal unconjugated
anti-Sepiapterin Reductase (SPR) (AA 1-261) antibodySPR 适用: 人 WB 宿主: 小鼠 Polyclonal unconjugated
anti-Sepiapterin Reductase (SPR) antibodySPR 适用: 人, 小鼠, 大鼠, 猴 WB, IHC 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 μg/μL
- 缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 储存条件
- -20 °C
- 储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- 有效期
- 12 months
-
- 抗原
- SPR (Sepiapterin Reductase (SPR))
- 别名
- SPR/Sepiapterin reductase (SPR 产品)
- 别名
- SDR38C1 antibody, AA409688 antibody, ENSMUSG00000071345 antibody, Gm10328 antibody, CG12117 antibody, Dmel\\CG12117 antibody, SR antibody, sptr antibody, xspr antibody, DDBDRAFT_0188686 antibody, DDBDRAFT_0191275 antibody, DDB_0188686 antibody, DDB_0191275 antibody, zgc:194446 antibody, sepiapterin reductase antibody, Sepiapterin reductase antibody, sepiapterin reductase L homeolog antibody, sepiapterin reductase b antibody, SPR antibody, Spr antibody, Sptr antibody, spr.L antibody, sprE antibody, CpipJ_CPIJ000511 antibody, sr antibody, spr antibody, sprb antibody
- 背景
-
Synonyms: SDR38C1, Sepiapterin reductase 7,8 dihydrobiopterin:NADP+ oxidoreductase, Sepiapterin reductase, Short chain dehydrogenase/reductase family 38C, member 1, SPR, SPRE_HUMAN.
Background: SPR, also known as sepiapterin reductase, is a homodimeric cytoplasmic protein that belongs to the sepiapterin reductase family. SPR functions as an NADH-dependent aldo-keto reductase and specifically catalyzes the reduction of pteridine derivatives. In addition, SPR plays an important role in tetrahydrobiopterin (BH4) biosynthesis, catalyzing the final reduction step of the synthesis pathway. BH4 is an essential cofactor for the hydroxylation of the aromatic amino acids (tryptophan, tyrosine and phenylalanine) and is required for proper dopamine synthesis. Mutations in the gene encoding SPR can cause sepiapterin reductase deficiency, a monoamine neurotransmitter deficiency without hyperphenylalaninemia. Sepiapterin reductase deficiency interferes with BH4 synthesis, resulting in DOPA-responsive dystonia and a variety of other human diseases. In addition, SPR mRNA expression is increased in the brain of Parkinson?s Disease (PD) patients, suggesting that SPR may play a role in PD.
- 途径
- Regulation of Systemic Arterial Blood Pressure by Hormones, Feeding Behaviour, Smooth Muscle Cell Migration
-
